This provides sufficient evidence to at least further explore the predictive ability of CRP in terms of chemotherapy outcomes and its inclusion as part of routine assessment for newly diagnosed NSCLC patients especially considering that CRP as a component of GPS has been proposed as a potential objective diagnostic tool for cancer cachexia [29] and has been shown to be a better prognostic factor than weight loss [30]. This evidence concerns the gene CRP and non-small cell lung carcinoma.